Ekf Diagnostics Share Price (EKF)

Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Ekf Diagnostics Holdings Plc LSE:EKF London Ordinary Share GB0031509804 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 30.20 0.00 01:00:00
Bid Price Offer Price High Price Low Price Open Price
28.40 32.00 0.00 0.00 0.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 44.92 5.52 0.81 37.3 138
Last Trade Time Trade Type Trade Size Trade Price Currency
- O 0 30.20 GBX
Related Shares
Smith & Nephew (SN.), Convatec (CTEC), Salvarx (SALV), Physiomics (PYC)

Ekf Diagnostics (EKF) Latest News

Ekf Diagnostics News

Date Time Source Headline
07/4/202007:00UKREGEKF Diagnostics Holdings PLC Final Results
24/3/202017:58ALNCEKF Diagnostics Still Planning First Payout With Trading Going Well
24/3/202008:23ALNCFAlliance News Flash Headline
24/3/202007:00UKREGEKF Diagnostics Holdings PLC Detailed trading review including COVID-19..
20/3/202007:00RNSNONEKF Diagnostics Holdings PLC Investor results briefing update
04/3/202007:00UKREGEKF Diagnostics Holdings PLC Notice of Results
24/2/202013:56UKREGEKF Diagnostics Holdings PLC Holding(s) in Company
29/1/202012:39ALNCEKF Diagnostic Expects Annual Results In Line With Expectations
29/1/202007:00UKREGEKF Diagnostics Holdings PLC Trading update
06/11/201918:01ALNCEKF Diagnostics Proposes Performance Bonuses Amid In-Line Trading
More Ekf Diagnostics News
Ekf Diagnostics Takeover Rumours

Ekf Diagnostics (EKF) Discussions and Chat

Ekf Diagnostics Forums and Chat

Date Time Title Posts
07/4/202008:35EKF Diagnostics for income and growth - A healthy, reliable combination!39
21/7/201911:30EKF Diagnostics - Growth by acquisition, expertise and special relationships1,375
27/7/201106:35EKF Diagnostics – Growth by acquisition, expert knowledge and special relationsh7
25/7/201114:22EKF Diagnostics209
13/7/201021:15EFK DIAGNOSTICS6

Add a New Thread

Ekf Diagnostics (EKF) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2020-04-08 16:15:0030.00400,000120,000.00O
2020-04-08 15:23:5230.74500153.72O
2020-04-08 15:20:3430.742,130654.85O
2020-04-08 15:08:4230.743,9031,199.94O
2020-04-08 14:53:5529.9938,34911,500.17O
View all Ekf Diagnostics trades in real-time

Ekf Diagnostics (EKF) Top Chat Posts

DateSubject
08/4/2020
09:20		Ekf Diagnostics Daily Update: Ekf Diagnostics Holdings Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker EKF. The last closing price for Ekf Diagnostics was 30.20p.
Ekf Diagnostics Holdings Plc has a 4 week average price of 16.93p and a 12 week average price of 16.93p.
The 1 year high share price is 37.70p while the 1 year low share price is currently 16.93p.
There are currently 457,632,749 shares in issue and the average daily traded volume is 569,260 shares. The market capitalisation of Ekf Diagnostics Holdings Plc is £138,205,090.20.
Read Full Thread
Reply
21/7/2019
11:21		wan: The initiation of a dividend would imply that EKF are seeing a strong trend in terms of profitable growth and cash generation. And it could therefore represent a signal that EKF are entering a new phase in terms of profitable growth and hopefully share price performance. Whilst the dividend payment is subject to shareholder approval in H1 2020, the dividend yield potential (based on today's share price) is quite reasonable at circa 3% and obviously potentially greater if this proves to be an interim dividend! Importantly, the dividend is not coming at the expense for the potential of further growth. The healthy cash and marketable securities position of £15m at the half-year (giving cash and marketable securities at current market value of over £20m) would imply that the dividend payout at circa £4.5m is likely to represent a relatively low payout ratio, meaning a healthy percentage of earnings will be retained for investing and growing the business. If realised and sustained, a combination of growth, share buybacks and dividends would certainly provide for healthy and reassuring combination! EKF's revenues are generated from the point of care (POC), central laboratory and life science divisions, with the largest contribution currently coming from POC. EKF have a large installed base of POC instruments which is growing and generates reliable recurring revenues. This impressive installed base of instruments is set for improved growth and provides for stable and predictable revenues, which adds good support to providing an on-going dividend policy. The Central Laboratory provides steady and reliable revenues, and with the significant investment and upgrade to the life Science enzyme facility enabling the Oragenics, Inc contract and also providing increased capacity to accommodate additional contracts, this division should start showing very good rates of growth. An investment in EKF provides good exposure to the central laboratory/life science and POC markets. The POC market is offering a combination of growth due to wider adoption, technological advancements and favourable demographic factors, as well as providing reliable revenues and relatively high barriers to entry, and thus offers defensive qualities as POC products associated with the effective diagnosis and management of medical conditions and disease are becoming evermore essential tools. The Central Laboratory division is providing an equally reliable income stream, but due to recent investments and expansion, this division has entered a new phase that has already started delivering good rates of growth. EKF have announced that it has entered into a non-exclusive Preferred Partner Arrangement (the “Agreement”) with Mount Sinai Innovation Partners (“MSIP”) - hTTp://ip.mountsinai.org/ In connection with the Agreement, the Company has signed a non-binding term sheet with Mount Sinai, which will allow the Company to explore the opportunity to support the licensing of technology originating from Mount Sinai to establish a novel digital health platform for earlier intervention in and better management of patients with Inflammatory Bowel Disease (“IBD”). Please conduct your own research when making investment decisions, as the originator, or the threads contributors, could be either wrong or inaccurate.
Read Full Thread
Follow
Reply
08/6/2019
10:20		pldazzle: wan - Another extract from the EKF accounts (note 7): 7. Dividends On 24th October 2018 the Company made a distribution in specie whereby the Company's shareholding in Renalytix AI plc, a developer of artificial intelligence enabled diagnostics for kidney disease, which has been floated separately from the Group, was distributed to ordinary shareholders of the Company. The rate was one Renalytix AI plc share for each 21.825 shares held in the company at a total value of £7,027,000 (2017: nil). The fair value per EKF share was 1.5357p, which has been calculated based on the market value of the Renalytix shares prior to the completion of the fundraising and their flotation on the AIM market, less a discount to account for the restrictions placed on the shares. That seems definitive.
Read Full Thread
Follow
Reply
07/6/2019
14:29		wan: Given the continued success being reflected in share price of Renalytix, has anyone else considered the fact that the £6.4m gain recognised on EKF's books, for the year ending 2018, for the spinout of Renalytix was discounted to take account of various factors including the restrictions on the shares which were distributed to EKF’s shareholders prior to the flotation? From the Annual Report - 29. Renalytix AI plc During 2018, the Group founded Renalytix AI plc which, along with its subsidiary company Renalytix AI Inc., were floated separately from the Group in November 2018. The investment in Renalytix was previously held as an asset available for sale. Renalytix is a developer of artificial intelligence-enabled diagnostics for kidney disease. As part of the creation of a separate business, intangible assets with a net value of £646,000 were sold to Renalytix by the Group, and the Group’s wholly owned subsidiary Renalytix AI Inc. was sold to Renalytix AI plc, in return for shares in Renalytix AI plc. Following these transactions, EKF’s shareholding in Renalytix comprised 20,964,295 ordinary shares. The EKF holding was then distributed in specie to Relevant EKF shareholders, being those on the EKF register as at the date of record for the distribution in October 2018 at a rate of one Renalytix AI plc ordinary share (a “RENX share”) for each 21.825 EKF ordinary shares held. The fair value of the shares distributed to Relevant EKF shareholders was calculated based on the proposed flotation price, less a discount to account for the restrictions placed on the shares. The discount was calculated taking into account, amongst other factors, the 180 day lock up period, sector volatility, and that the shares were issued pre-admission. The total fair value of the distributed shares was calculated as £7,027,000 with the profit on disposal, which has been shown as an exceptional profit, being calculated net of expenses of £25,000 and the value of the intangible asset transferred of £6,356,000. Subsequent to the distribution, EKF invested £3.1m in the shares of Renalytix at the same price as other new investors and, as at the date of this announcement, holds 2,577,907 RENX shares. (END) That appears to indicate that the Renalytix shares were discounted back to circa 33.5p, so again it appears to indicate that there is potentially another very healthy exceptional gain to be realised. Not to mention that EKF, having purchased further shares in Renalytix, now own over 2.6 million shares at an average price of 123p.
Read Full Thread
Follow
Reply
09/2/2019
09:04		macarona: Hi Wan, what do you see as the fair share price value for EKF?
Read Full Thread
Follow
Reply
28/10/2018
06:56		wan: Cambridgedon...If we take 40p (Market cap £183m) as having fully realised, in share price terms, the soluble Tumor Necrosis Factor Receptors 1 and 2 (sTNFR1/2) biomarker assets, and then factor in EKF receiving in round figures £25m (20,964,524 RENX Shares @ £1.21) for those assets, that should result in a ex distribution share price (reduction) to circa 35p (market cap £160m) However, 40p may have been driven by increased demand ahead of the spin-out, but even if we targeted 35p as discounting the effects of such demand, then we would arrive at an ex distribution share price of 30p (hence previous comments) From the point of announcing the spin-out (11th Jan 2018 share price circa 26p), if one looks at specific announcements and other stated growth initiatives, which are over and above that associated with Renaltix, then there is very good reason to expect an increase in organic growth over the near term and a significant increase in growth over the medium term.
Read Full Thread
Follow
Reply
23/10/2018
15:34		wan: Macarona...As discussed on here previously, the current EKF share price appears to have already reflected the distribution, presumably because the announcements had effectively flagged when and by how much, but as I said this morning, time will tell None of us can predict what will happen when Renalytix commences trading, but having done quite a bit of research I am quite hopeful about the near to medium term prospects for Renalytix (including potential news flow), and maybe there will be good demand for the shares (other AI in healthcare companies are certainly attaining very high valuations). So my decision to buy more EKF shares was based on the current share price pullback and the near term prospects and potential news flow for EKF, and also about getting the maximum exposure to Renalytix ahead of any high demand and potentially being scaled back on the Restricted Offer, via which I intend to also add (and possibly when trading commences too). Best wishes to all EKF and Renalytix shareholders.
Read Full Thread
Follow
Reply
23/10/2018
08:13		cambridgedon: Hi All, Thanks Wan. The ratio of new shares to old is a little better than we originally calculated. Surprised at the record date but not complaining as added recently. I'll be happier when the EKF price gets back to the high 30's where it should be all things considered. CD
Read Full Thread
Follow
Reply
20/10/2018
08:32		wan: Cambridgedon...As I said previously, there is a lot to digest! I assume we will know early next week regarding the de minimis threshold, but one assumes that what ever that threshold is, it will then be based on a round number. There are 457,554,636 shares in issue, which in your scenario would be closer to 45 or 46 shares per 1000 EKF shares. As Ingroid suggests, the current EKF share price does appear to reflect the distribution (as per the case when a stock goes ex dividend), but you will have to wait six months to ultimately realise it (if you wanted to sell). Personally speaking, I was not looking to immediately sell the Renalytix shares anyway (as I had good reasons to think that the investment prospect would be a good one), so I am not fazed by the lock-up period. I note Renalytix will also pay back all the EKF loans, so there is some cash to come back too. Overall, I am very impressed with the know-how and expertise behind Renalytix, including how they have assessed the proposition and positioned Renalytix to address the market, which is indeed very large (as are the resulting savings and resultant business proposition). EKF clearly see a good investment proposition too, as they intend to take part in the fund raise and have a notifiable interest in Renalytix. Renalytix aside, I still think that EKF is an excellent long term investment.
Read Full Thread
Follow
Reply
16/10/2018
10:50		cambridgedon: Don't bother to call the "helpline", they have not even heard of EKF nor Renalytix AI! I've told N+1 Singer who were not impressed. From what I can gather the ratio of free shares to your existing holding will not be known until after the GM on Friday or some other later date. As to how many new shares you can subscribe for at £1.21, should you wish, I've no idea. If Wan or anyone else can shed some light on all of this I'd be grateful. Also, the share price keeps heading lower too. All very odd. CD
Read Full Thread
Follow
Reply
20/7/2016
11:58		andrewbaker: The recent share purchase (see news articles on quotes page) suggests that the company is prospering/will prosper greatly going forward. The weakness of the £ sterling combined with sales in US$ and other currencies is a big boost for many British businesses; and if their core product(s) are improving in sales/prospects too, that's a double bonus. A continuing rise in the EKF share price looks very much on the cards right now and going forward.
Read Full Thread
Follow
Reply
Ekf Diagnostics share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
EKF
Ekf Diagno..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200409 07:01:07